Sandoz Group AG/ CH1243598427 /
2024-05-31 5:19:50 PM | Chg. +0.70 | Volume | Bid5:20:00 PM | Ask5:20:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
32.24CHF | +2.20% | 94,711 Turnover: 3.04 mill. |
-Bid Size: - | -Ask Size: - | 14.47 bill.CHF | - | - |
GlobeNewswire
05-22
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
04-30
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire
04-30
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
04-22
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire
03-21
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire
03-04
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire
02-29
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire
01-31
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire
01-22
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire
2023-11-21
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve pa...